Neurology: Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study

Neurology: Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study is organized by American Academy of Neurology (AAN).

Dates:
Released: 2/20/2018
Expires: 2/20/2021

Accreditation:
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives:
Upon completion of the article by Murata et al, the participant should be able to:
• Briefly discuss the possible antiparkinsonian mechanism of action of zonisamide
• Describe the effect of zonisamide on motor function, cognitive function, caregiver burden, and behavioral and psychological symptoms in this study
• Discuss the rate of adverse effects in patients receiving zonisamide vs placebo in this study

Additional details will be posted as soon as they are available.